CAS: 186826-70-0

Applications (3β)-16-[(3β)-3-Hydroxyandrosta-5,16-dien-17-yl]-17-(3-pyridinyl)-androsta-5,16-dien-3-ol is a derivative of Abiraterone (A108490), which is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer. References Denis, L., et al.: Cancer, 72, 3888 (1993), Potter, G.A., et al.: J. Med. Chem., 38, 2463 (1995), Denmeade, S., et al.: Nat. Rev., 2, 389(2002), Scher, H., et al.: J. Clin. Oncol., 23, 8253 (2005),

Abiraterone dimer impurity is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs. It is also a metabolite of abiraterone and has been detected in the urine of patients receiving the drug. Abiraterone dimer impurity is found in trace amounts in abiraterone acetate but its pharmacological significance is not known. This impurity has been detected in the urine of patients receiving abiraterone acetate therapy.